The strong ORR data and ODD status support rezatapopt's regulatory and commercial potential, but the widening loss and lack of revenue underscore ongoing dilution risk. Traders should monitor enrollment progress toward NDA submission in 2027 and any future partnership or funding announcements.
Price Chart
Executive Summary
PMV Pharmaceuticals reported financial results for 2025, highlighted by advancing its lead drug rezatapopt in the Phase 2 PYNNACLE trial for ovarian cancer, achieving a 50% ORR in the ovarian cohort, securing Orphan Drug Designation from the FDA, and maintaining a cash runway into Q2 2027. The company's net loss widened to $77.7 million as R&D spending increased, while G&A costs declined due to restructuring.
Key Financial Metrics
Key Facts
- Rezatapopt showed a 50% overall response rate (ORR) in 48 evaluable platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutation as of post-September 2025 data cut-off.
- FDA granted Orphan Drug Designation (ODD) for rezatapopt for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers.
- NDA submission for rezatapopt in ovarian cancer planned for Q1 2027.
- Cash, cash equivalents, and marketable securities totaled $112.9 million as of December 31, 2025, providing cash runway into Q2 2027.
- Net loss for 2025 was $77.7 million, up from $58.7 million in 2024, driven by higher R&D expenses ($69.9M vs $58.5M).
- G&A expenses decreased to $16.3M from $26.9M due to facility relocation and staff reductions.
Financial Impact
Increased R&D spend by $11.4M YoY; net loss expanded by $19M; cash burn from operations was $73.6M in 2025.
Risk Factors
- Clinical development risk: Phase 2 data is interim and may not hold in larger trials or lead to approval.
- Regulatory risk: NDA acceptance and approval are not guaranteed despite ODD and Fast Track status.
- Cash runway ends mid-2027; likely need for equity financing before approval, leading to potential dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250995 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.52%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers